News Release

Ashland introduces Vialose™ trehalose dihydrate, a high purity lyoprotectant and stabilizer for biologic medicines and other parenteral formulations at Excipient World in Kissimmee, Florida

New product featured in Ashland Booth 301

WILMINGTON, Del., May 2, 2022 – Ashland is launching, Vialose™ trehalose dihydrate, the newest addition to its portfolio of parenteral excipients for injectable formulations. The product will be featured during the Excipient World Conference in Kissimmee, Florida, May 3-4, 2022, in Ashland booth #301.

Vialose™ trehalose dihydrate is Ashland's trehalose dihydrate, a functional ingredient used to protect and stabilize proteins for biologic medicines. It is manufactured in the United States (U.S) to the following quality standards: *USP-NF* <1078> and *The Joint IPEC-PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients*. It is compliant with the NF, EP, JP and ChP monograph requirements.

"Ashland is continuously solving to provide our customers with value-added solutions to their formulation challenges and excipient needs," said Dean Ross, strategic marketing manager pharmaceuticals, Ashland. "The launch of Vialose™ trehalose dihydrate adds to our portfolio of functional excipients for injectable formulations that allow our customers to develop beneficial medicines for optimal health."

During Excipient World, Ashland will also highlight recently launched Benecel™ XRF hpmc controlled release matrix formers and titanium dioxide free film coatings.

Benecel™ XRF HPMC controlled release matrix formers

Hypromellose continues to be the most successful polymer for hydrophilic matrix tablets, the dominant technology for controlled-release applications. Benecel™ XRF hpmc products have been optimized for controlled-release matrix tablets providing robust tablets and consistent drug release, especially for high speed tableting operations. Additionally, Benecel™ XRF hpmc is an ideal choice for multilayer tablets, providing superior interfacial bonding and layer strength.

Aquarius™ TF film coatings

Aquarius™ TF film coatings systems meet anticipated regulatory and application needs and create a strong solution to answer the call for more health-conscious coating choices and

protect sensitive tablet cores. The versatile coating system improves performance characteristics and maximizes product quality and enhances processing efficiency.

Aquarius™ TF is fully formulated without the use of titanium dioxide as the opacifier filler and achieves the desired appearance and performance of film coatings while providing superior opacity, brightness and aesthetics to tablets compared to other TF coatings. Available in a wide range of solid applications (10% to 30%) and polymer based as well as a wide selection of pigmented options.

To partner with Ashland and learn more about Ashland's excipient products, visit the company at the Excipient World booth 301 or at ashland.com/pharmaceutical

About Ashland
Ashland Global Holdings Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for sustainability. The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 3,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit Ashland.ashland.com and ashland.com/sustainability to learn more.

FOR FURTHER INFORMATION:

Media Relations
Nina Servino
janina.servino@ashland.com

##